Back
48
Day Range
$332.38
$339.26
52-Week Range
$328.23
$404.87
Volume
1,595,256
50D / 200D Avg
$363.32
/
$372.67
Prev Close
$335.67
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 39.2 | 0.4 |
| P/B | 5.7 | 2.9 |
| ROE % | 15.1 | 3.8 |
| Net Margin % | 12.9 | 3.9 |
| Rev Growth 5Y % | 10.1 | 10.0 |
| D/E | 0.7 | 0.2 |
Key Takeaways
Revenue grew 10.07% annually over 5 years — strong growth
ROE of 15.08% — decent returns on equity
Generating 4.28B in free cash flow
P/E of 39.21 — premium valuation
Cash machine — converts 131.95% of earnings into free cash flow
Capital efficient — spends only 3.03% of revenue on capex
Growth
Revenue Growth (5Y)
10.07%
Revenue (1Y)11.16%
Earnings (1Y)8.45%
FCF Growth (3Y)16.87%
Quality
Return on Equity
15.08%
ROIC9.84%
Net Margin12.92%
Op. Margin19.47%
Safety
Debt / Equity
0.66
Current Ratio1.89
Interest Coverage8.05
Valuation
P/E Ratio
39.21
P/B Ratio5.68
EV/EBITDA28.25
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11.16% | Revenue Growth (3Y) | 10.69% |
| Earnings Growth (1Y) | 8.45% | Earnings Growth (3Y) | 1.27% |
| Revenue Growth (5Y) | 10.07% | Earnings Growth (5Y) | 12.96% |
| Profitability | |||
| Revenue (TTM) | 25.12B | Net Income (TTM) | 3.25B |
| ROE | 15.08% | ROA | 6.78% |
| Gross Margin | 63.96% | Operating Margin | 19.47% |
| Net Margin | 12.92% | Free Cash Flow (TTM) | 4.28B |
| ROIC | 9.84% | FCF Growth (3Y) | 16.87% |
| Safety | |||
| Debt / Equity | 0.66 | Current Ratio | 1.89 |
| Interest Coverage | 8.05 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 39.21 | P/B Ratio | 5.68 |
| P/S Ratio | 5.07 | PEG Ratio | 5.16 |
| EV/EBITDA | 28.25 | Dividend Yield | 0.01% |
| Market Cap | 127.28B | Enterprise Value | 138.13B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 25.12B | 22.60B | 20.50B | 18.45B | 17.11B |
| Net Income | 3.25B | 2.99B | 3.17B | 2.36B | 1.99B |
| EPS (Diluted) | 8.40 | 7.76 | 8.25 | 6.17 | 5.22 |
| Gross Profit | 16.07B | 13.98B | 12.49B | 11.04B | 10.71B |
| Operating Income | 4.89B | 5.06B | 4.28B | 3.73B | 3.76B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 47.84B | 42.97B | 39.91B | 36.88B | 34.63B |
| Total Liabilities | 25.42B | 22.34B | 21.32B | 20.27B | 19.75B |
| Shareholders' Equity | 22.42B | 20.63B | 18.59B | 16.62B | 14.88B |
| Total Debt | 14.86B | 14.12B | 13.49B | 13.53B | 12.90B |
| Cash & Equivalents | 4.01B | 3.65B | 2.97B | 1.84B | 2.94B |
| Current Assets | 14.76B | 14.85B | 12.52B | 10.28B | 10.02B |
| Current Liabilities | 7.79B | 7.62B | 7.92B | 6.30B | 4.55B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#429 of 1024
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026